摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Levocabastine hydrochloride | 79516-67-9

中文名称
——
中文别名
——
英文名称
Levocabastine hydrochloride
英文别名
(3S,4R)-1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenylpiperidine-4-carboxylic acid;hydron;chloride
Levocabastine hydrochloride化学式
CAS
79516-67-9;79547-78-7;80185-65-5;85441-07-2;85441-08-3;85441-38-9
化学式
C26H29FN2O2*ClH
mdl
——
分子量
456.988
InChiKey
OICFWWJHIMKBCD-SFUPJVRMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    DMSO:~10 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    5.32
  • 重原子数:
    32
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    64.3
  • 氢给体数:
    2
  • 氢受体数:
    5

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
◉ 母乳喂养期间使用总结:由于眼部吸收有限,预计左卡巴斯汀不会对哺乳婴儿产生任何不良反应。为了显著减少使用眼药后药物到达母乳的量,可以在眼角处对泪点施加压力1分钟或更长时间,然后用吸收性纸巾去除多余的溶液。 ◉ 对哺乳婴儿的影响:截至修订日期,未找到关于左卡巴斯汀的相关已发布信息。在一项电话随访研究中,母亲报告有10%的婴儿在接触各种抗组胺药后出现烦躁和肠绞痛症状,1.6%的婴儿出现嗜睡。所有反应均未需要医疗关注。 ◉ 对泌乳和母乳的影响:在非哺乳期妇女和产后早期妇女中,通过注射给予相对高剂量的抗组胺药可以降低基础血清催乳素。然而,吸吮诱导的催乳素分泌不会受到产后母亲抗组胺药预处理的影响。尚未研究较低口服剂量的抗组胺药是否对血清催乳素有相同的影响,或者对催乳素的影响是否对母乳喂养成功有任何影响。在已建立泌乳的母亲中,催乳素平可能不会影响她的哺乳能力。
◉ Summary of Use during Lactation:Because absorption from the eye is limited, levocabastine would not be expected to cause any adverse effects in breastfed infants. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. ◉ Effects in Breastfed Infants:Relevant published information on levocabastine was not found as of the revision date. In one telephone follow-up study, mothers reported irritability and colicky symptoms 10% of infants exposed to various antihistamines and drowsiness was reported in 1.6% of infants. None of the reactions required medical attention. ◉ Effects on Lactation and Breastmilk:Antihistamines in relatively high doses given by injection can decrease basal serum prolactin in nonlactating women and in early postpartum women. However, suckling-induced prolactin secretion is not affected by antihistamine pretreatment of postpartum mothers. Whether lower oral doses of antihistamines have the same effect on serum prolactin or whether the effects on prolactin have any consequences on breastfeeding success have not been studied. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
来源:Drugs and Lactation Database (LactMed)

制备方法与用途

生物活性

Levocabastine hydrochloride(R 50547)是一种长效、高效且选择性的组胺 H1 受体拮抗剂,具有抗过敏活性。此外,它也是一种选择性、高亲和力的神经降压素受体亚型2 (NTR2) 拮抗剂,对 mNTR2 的 Ki 值为 17 nM。

靶点
H1 受体 NTR2 17 nM (Ki)
体内研究

Levocabastine(0.25 mg/kg;i.p.,每天两次,连续五天,豚鼠)能够抑制病毒引起的气道高反应性、减少支气管肺泡细胞的涌入和白蛋白含量的增加,并纠正对酵母刺激下支气管肺泡细胞产生化学发光的降低。在给予β-LT的小鼠中,Levocabastine(0.05 mg/kg;i.p.)能阻断β-LT 的镇静作用,减少头部点头次数。

文献信息

  • [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
    申请人:ALMIRALL SA
    公开号:WO2014060432A1
    公开(公告)日:2014-04-24
    New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)
    新的吡咯三唑酮生物具有化学结构式(I),公开;以及它们的制备方法,包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶(PI3Ks)抑制剂在治疗中的应用。
  • New CRTh2 antagonists
    申请人:Almirall, S.A.
    公开号:EP2548876A1
    公开(公告)日:2013-01-23
    The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
    本发明涉及式(I)的化合物,制备这种化合物的方法以及它们在治疗病理状况或疾病中的应用,该病理状况或疾病容易通过CRTh2拮抗活性得到改善。
  • Azabicycloalkane compounds
    申请人:——
    公开号:US20040242622A1
    公开(公告)日:2004-12-02
    This invention provides compounds of formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both &bgr; 2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Such compounds are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
    这项发明提供了式I的化合物: 其中R1、R2、R3、R4、R5、R6和R7如规范中所定义,或其药用可接受盐、溶剂或立体异构体。本发明的化合物具有β2肾上腺素受体激动剂和肌碱受体拮抗剂活性。这些化合物对治疗肺部疾病,如慢性阻塞性肺病和哮喘,是有用的。
  • TROPAN COMPOUND
    申请人:ONO PHARMACEUTICAL CO., LTD.
    公开号:EP1785421A1
    公开(公告)日:2007-05-16
    The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.
    传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难,并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式(I)表示的化合物: (其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型,或它们的混合物),其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂,具有减少副作用或不良反应。
  • [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DE PI3K
    申请人:ALMIRALL SA
    公开号:WO2012146666A1
    公开(公告)日:2012-11-01
    New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks).
    披露了具有公式(I)化学结构的新型吡咯三嗪酮生物;以及它们的制备方法,包含它们的药物组合物以及它们作为磷脂酰肌醇3-激酶(PI3Ks)抑制剂在治疗中的用途。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺